Table 1 Baseline characteristics of the patients at the time of completing the MISS questionnaire
Characteristics | N = 120 |
|---|---|
Qualitative | |
Female (%) | 103 (85.8) |
MTX, subcutaneous (%) | 66 (55) |
MTX dose (mg/week) | |
< 10 (%) | 1 (0.8) |
10.1–17.5 (%) | 31 (25.8) |
> 17.5 (%) | 88 (73.4) |
Leflunomide (%) | 29 (24.2) |
Nonsteroidal anti-inflammatory drugs (%) | 9 (7.5) |
Disease-modifying antirheumatic drugs – biological (%) | 28 (23.3) |
Corticosteroids (%) | 63 (52.5) |
Proton-pump inhibitors (%) | 56 (46.7) |
Antiemetics (%) | 1 (0.8) |
Folic acid | |
No (%) | 7 (5.8) |
5 mg/week (%) | 92 (76.7) |
10 mg/week or more (%) | 21 (17.5) |
DAS 28 moderate and high disease activity (%) | 51 (45.5) |
Smoking | |
No (%) | 74 (62.2) |
Current smoker (%) | 15 (12.6) |
Ex-smoker (%) | 30 (25.2) |
Seropositive RA (%) | 92 (76.7) |
Hypertension (%) | 68 (56.7) |
Diabetes mellitus (%) | 29 (24.2) |
Dyslipidemia (%) | 36 (30.0) |
Hypothyroidism (%) | 15 (12.5) |
Fibromyalgia (%) | 10 (8.3) |
Gastroesophageal reflux disease (%) | 12 (10.3) |
Antidepressant (%) | 24 (20) |
Quantitative | |
Mean age, years (SD) | 61 (12.5) |
Mean disease duration, years (SD) | 16 (10.3) |
Mean MTX usage duration, years (SD) | 7 (5.5) |
Mean dose of MTX, mg/week (SD) | 20 (5.1) |
Mean DAS28 (SD) | 3.25 (3.1) |